Approximately C$90M raised to date. Well-funded to progress clinical trials and M&A strategy.
Commenced trading on NEO EXCHANGE and MJDS eligible for US listing.
Canada’s largest go-public financing round in the psychedelic sector by raising C$45M. Strategic shareholder base of round subscribed to by top US biotech funds e.g., Janus Henderson, LifeSci Ventures and RA Capital.
Deep Experience in healthcare, M&A, and capital markets.
CEO with over 30 years in the healthcare sector and has raised over US$4B in capital and has led over US$5B in M&A activity.
Successfully helped develop widely-used drugs: Allegra, Sabril, Anzemet & Vaniqa.
300 combined peer-reviewed publications by scientific leadership include work in addiction and psychedelics.
Overseen 60+ IND programs with FDA.
Acquired Boston-based pharmaceutical company ADELIA THERAPEUTICS INC.
Inked technology partnership with KERNEL to leverage breakthrough neuroimaging in upcoming clinical trials.
10 Patent Filings cover:
Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
API Modification
Develop new APIs via selective modifications of tryptamine and phenethylamine-based scaffolds specifically to alter their pharmacokinetics without modifying their therapeutic potential.
Modifications involve replacing selective hydrogens with deuterium atoms.
Optimizing unique physicochemical attributes e.g. salts, crystal forms, co-crystals, etc.
Research and Develop
Efficient delivery system that attempts to bypass the liver metabolism with a direct path to the brain providing a faster onset.
Modified-release formulations with the potential to reduce side effects and to control exposure.
Dose control through proprietary device platform.
Delivery systems may be applied to many psychedelic compounds.
Science Meets Technology
Software-based platform to gather clinical research data from psychedelic treatment.
Machine learning-based data analytics for improved patient outcomes.
Patient therapy and integration support.
This plan is suitable for the beginner IT specialist and will allow you to familiarize yourself with all the main functions of the service.
This plan is suitable for the freelancers and will allow you to familiarize yourself with all the main functions of the service.
Experience
Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:
Leadership
Experienced CEO with over 30 years in the healthcare sector, raised over US$4B in capital and has led over US$5B in M&A activity.
Research & Knowledge
300 combined peer-reviewed publications by scientific leadership including work in addiction and psychedelics.
Overseen 60+ investigational New Drug Programs with the Food and Drug Administration.
Experienced team
The only scientific team to have successfully commercialized a psychedelic drug to date.
Supported the successful commercialization of widely-used drugs including: Allegra, Sabril, Anzement & Vaniqa with sales over $2B.
Development Pipeline
10 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
see our programsAcquisitions & Partnerships
see partnerships
“We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."
Our relentless pursuit to commercialize these revolutionary treatments is supported by our diverse team of scientific and business experts. Our group brings the following expertise:
10 patent filings covering: Novel psychedelic compounds, delivery mechanisms, supportive treatment platforms and a drug discovery pipeline of modified and novel tryptamines and phenethylamines.
see our programsAcquired and successfully integrated Boston-based pharmaceutical company bringing immense experience in the scientific and psychedelic sectors.
Partnered with technology leader to leverage breakthrough neuroimaging hardware and software in upcoming clinical trials.
“We are focused on addressing the mental health crisis and transforming the treatment landscape. To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients."
